News

Woo-Yang Kim, Ph.D., associate professor, developmental neuroscience, led a team of researchers from UNMC and Creighton University into a deeper exploration of a genetic mutation that reduces the

ABP 215, which is a biosimilar to Avastin (bevacizumab), has been recommended for marketing authorization to treat certain types of cancer, including in combination with fluoropyrimidine-based chemotherapy for

The JV was formed in September 2012 by Pfizer with Zhejiang Hisun Pharmaceuticals (Hisun) with a total investment of $295m and a capital of $250m. Hisun will remain

PREVYMIS is indicated for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). CMV is a

Brexanolone achieved the primary endpoint in both trials, a mean reduction from baseline in the Hamilton Rating Scale for Depression (HAM-D) total score compared to placebo at 60

The deal gives Sanofi an exclusive, worldwide license to develop and commercialize PRN2246, which is presently in clinical development. Under the deal, Principia will receive $40m upfront payment, future milestone payments

Under the deal, the partnership will use MiNA’s small activating RNA (saRNA) therapeutics platform to develop novel compounds for the treatment of fibrotic liver diseases such as NASH.

The operation positions Cerenis at the forefront of the chemotherapy drug delivery and immuno-oncology space. This represents a significant step towards the Company’s strategic objective of developing the

Wellington Management Company LLP, Venrock Healthcare Capital Partners and Cormorant Asset Management joined existing investors OrbiMed, Longitude Capital, Sibling Capital Ventures, Limulus Venture Partners and Vivo Capital in the round. Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical